Skip to Content Facebook Feature Image

Buxton homers twice, Ryan works 7 scoreless innings as Twins end 7-game skid by beating Nationals

Sport

Buxton homers twice, Ryan works 7 scoreless innings as Twins end 7-game skid by beating Nationals
Sport

Sport

Buxton homers twice, Ryan works 7 scoreless innings as Twins end 7-game skid by beating Nationals

2024-05-22 09:17 Last Updated At:09:20

WASHINGTON (AP) — Byron Buxton hit two homer and drove in three runs, Joe Ryan pitched seven scoreless innings and the Minnesota Twins halted a seven-game losing streak with a 10-0 victory over the Washington Nationals on Tuesday night.

Jose Miranda added a two-run homer as the Twins scored eight runs off Nationals left-hander Patrick Corbin (1-5). Willi Castro added a two-run shot off reliever Jacob Barnes as Minnesota responded following a players-only meeting after Monday night's 12-3 loss in the series opener.

More Images
Minnesota Twins starting pitcher Joe Ryan throws to a Washington Nationals batter during the second inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

WASHINGTON (AP) — Byron Buxton hit two homer and drove in three runs, Joe Ryan pitched seven scoreless innings and the Minnesota Twins halted a seven-game losing streak with a 10-0 victory over the Washington Nationals on Tuesday night.

Minnesota Twins' Byron Buxton hits a home run against the Washington Nationals during the second inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton hits a home run against the Washington Nationals during the second inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Carlos Correa runs to third on his triple against the Washington Nationals during the first inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Carlos Correa runs to third on his triple against the Washington Nationals during the first inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his home run against the Washington Nationals during the second inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his home run against the Washington Nationals during the second inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Washington Nationals starting pitcher Patrick Corbin throws to a Minnesota Twins batter during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Washington Nationals starting pitcher Patrick Corbin throws to a Minnesota Twins batter during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his two-run home run against the Washington Nationals during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his two-run home run against the Washington Nationals during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins starting pitcher Joe Ryan throws to a Washington Nationals batter during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins starting pitcher Joe Ryan throws to a Washington Nationals batter during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his two-run home run against the Washington Nationals during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his two-run home run against the Washington Nationals during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Overall, the Twins scored more runs in the game than in the first six games of their skid combined.

Corbin allowed nine hits and three walks, and all of his season-worst eight runs allowed were earned.

Jacob Young had two of Washington's three hits as the Nationals were shut out for the third time in seven games. The loss came a day after snapping their own five-game losing streak.

Buxton has had hits in all three of his starts in his return after missing 14 games due to right knee inflammation.

He opened Tuesday's scoring in the second when he took Corbin's 0-1 offering the opposite way for a solo shot. In the fifth, he drove a two-run homer, his third of the season, slightly closer to dead center to stretch Minnesota's advantage to 6-0.

That was more than enough support for Ryan (3-3), who allowed three hits and two walks in his first scoreless outing since June of last season.

Both free passes came in Ryan's final inning, marking just the second time a Nationals runner reached scoring position. He got out of the inning by fanning Joey Gallo for his sixth strikeout.

TRAINERS ROOM

Twins: 3B/SS Royce Lewis (right quad strain) ran the bases on Monday for the first time since going on the 10-day injured list in late March. ... RHP Josh Winder (scapular stress fracture) was slated continue his rehab assignment by throwing two-plus innings for Triple-A St. Paul on Tuesday and Friday. He's allowed eight runs — seven earned — in his first five rehab outings.

Nationals: OF Lane Thomas (left knee sprain) went 0 for 3 and stole a base in his first rehab game Tuesday for Double-A Harrisburg. He will play again on Wednesday.

UP NEXT

Nationals RHP Jake Irvin (2-4, 3.91 ERA), a Twin Cities area native and former Twins draft selection in high school, pitches for the first time against Minnesota, which sends rookie RHP Simeon Woods Richardson (1-0, 2.97 ERA).

AP MLB: https://apnews.com/hub/mlb

Minnesota Twins starting pitcher Joe Ryan throws to a Washington Nationals batter during the second inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins starting pitcher Joe Ryan throws to a Washington Nationals batter during the second inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton hits a home run against the Washington Nationals during the second inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton hits a home run against the Washington Nationals during the second inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Carlos Correa runs to third on his triple against the Washington Nationals during the first inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Carlos Correa runs to third on his triple against the Washington Nationals during the first inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his home run against the Washington Nationals during the second inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his home run against the Washington Nationals during the second inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Washington Nationals starting pitcher Patrick Corbin throws to a Minnesota Twins batter during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Washington Nationals starting pitcher Patrick Corbin throws to a Minnesota Twins batter during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his two-run home run against the Washington Nationals during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his two-run home run against the Washington Nationals during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins starting pitcher Joe Ryan throws to a Washington Nationals batter during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins starting pitcher Joe Ryan throws to a Washington Nationals batter during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his two-run home run against the Washington Nationals during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Minnesota Twins' Byron Buxton celebrates his two-run home run against the Washington Nationals during the fifth inning of a baseball game Tuesday, May 21, 2024, in Washington. (AP Photo/Nick Wass)

Next Article

Takeaways from AP's report on access to gene therapies for rare diseases

2024-06-21 12:42 Last Updated At:12:50

The promise of gene therapy looms large for families dealing with rare, genetic disorders. Such treatments offer the possibility of one-time cures.

But families and researchers worry such therapies will remain out of reach.

Collectively, about 350 million people worldwide suffer from rare diseases, most of which are genetic. But each of the 7,000 individual disorders affects perhaps a few in a million people or less. So there’s little commercial incentive to develop or bring to market these one-time therapies to fix faulty genes or replace them with healthy ones.

The Associated Press examined what this means for families, scientists and the nascent field of gene therapy.

Here are key takeaways from AP's report.

Camden Alderman was diagnosed as a baby with a rare disease called Wiskott-Aldrich syndrome, which is caused by a mutated gene on the X chromosome. It primarily affects boys – up to 10 out of every million — and can cause frequent infections, eczema and excessive bleeding.

When he was a toddler, doctors removed his spleen because of uncontrolled bleeding. As a young boy, he wound up in the hospital many times and was told he couldn’t play baseball.

His mother Robin Alderman recalls one doctor saying: “Basically, your son’s only chance at a cure is going to be gene therapy.”

He also told her researchers weren’t then accepting U.S. residents into a clinical trial for the treatment, which “just kind of broke my heart,” she said. There's still no clinical trial he can join, and London-based Orchard Therapeutics stopped investing in an experimental treatment for the condition in 2022.

Lacey Henderson’s daughter, 5-year-old Estella, has alternating hemiplegia of childhood, a neurological condition that affects 300 people in the U.S. Estella is cognitively delayed, has limited use of her hands and suffers episodes that temporarily paralyze part or all of her body, Henderson said. Medications can curb symptoms, but there’s no cure.

Her Iowa family raises money through a GoFundMe and a website to develop a gene therapy. They’ve brought in around $200,000.

“We have three different projects with various researchers,” Henderson said. “But the problem is everything is underfunded.”

The amount of work it takes to get from a lab to human testing and through the drug approval process is “incredibly expensive,” said Dr. Donald Kohn, professor of microbiology, immunology and molecular genetics at the University of California, Los Angeles.

In the last couple of years, he said, investment in gene therapy has largely dried up.

“If you have to spend $20 million or $30 million to get approval and you have five or 10 patients a year, it’s hard to get a return on investment,” Kohn said. “So we have successful, safe therapies, but it’s more the financial, economic elements that are limiting them from becoming approved drugs."

Ultimately, most biotechnology companies become public and must focus on shareholder profit, said Francois Vigneault, CEO of the Seattle biotech Shape Therapeutics.

“The board is the thing that gets in the way; they’re trying to maximize gain,” said Vigneault, whose company is privately held. “That’s just greed. That’s just incentive misaligned between corporate company structure and what we should do that’s good for the world.”

In the U.S., for example, The Bespoke Gene Therapy Consortium was organized by the Foundation for the National Institutes of Health and includes the FDA, various NIH institutes and several drug companies and nonprofits. Its goals include supporting a handful of clinical trials and streamlining regulatory processes.

Researchers are trying to address the problem scientifically. Dr. Anna Greka said the Broad Institute of MIT and Harvard has launched an effort to look at the commonalities behind various conditions — or nodes, which can be likened to branches meeting at a tree trunk. Fixing the nodes with gene therapies or other treatments, rather than particular “misspellings” in DNA responsible for one disorder, could potentially address multiple diseases simultaneously.

“What this does is it increases the number of patients who can benefit from the therapy,” said Greka, a Broad member.

Still, scientists say these efforts don’t negate the larger financial quandary surrounding therapies for rare diseases, and it may be a while before such gene therapies are available to patients worldwide.

“This is a massive challenge, and I’m not entirely sure we’re going to be able to overcome it,” said Claire Booth of University College London. “But we have to give it a go because we’ve spent decades and millions making these transformative treatments. And if we don’t try, then it feels like the end of an era.”

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

FILE - This undated image made available by the National Human Genome Research Institute shows the output from a DNA sequencer. Collectively, about 350 million people worldwide suffer from rare diseases, most of which are genetic. But each of the 7,000 individual disorders affects perhaps a few in a million people or less. So there’s little commercial incentive to develop or bring to market these one-time therapies to fix faulty genes or replace them with healthy ones. (NHGRI via AP, File)

FILE - This undated image made available by the National Human Genome Research Institute shows the output from a DNA sequencer. Collectively, about 350 million people worldwide suffer from rare diseases, most of which are genetic. But each of the 7,000 individual disorders affects perhaps a few in a million people or less. So there’s little commercial incentive to develop or bring to market these one-time therapies to fix faulty genes or replace them with healthy ones. (NHGRI via AP, File)

Recommended Articles